drugset / Trial / NCT06942156

Optimize Immunosuppressive Therapy Using Everolimus and Low-dose Calcineurin Inhibitors in Heart Transplant Patients in Korea

NCT06942156

Phase 4 Not yet recruiting 140 enrolled Chong Kun Dang Pharmaceutical
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the efficacy and safety of lower dose calcineurin inhibitors (CNI) in combination with Everolimus in Korean heart transplant recipients.

Timeline

Start
2025-08-14
Primary completion
2030-12
Completion
2030-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Everolimus Small molecule 1.5 g
Comparator Mycophenolate Mofetil Small molecule 1.5 g

Indications

No indication recorded.